about
Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolamAdverse effects after the use of JWH-210 - a case series from the EU Spice II plus project.Activity-Based Detection of Consumption of Synthetic Cannabinoids in Authentic Urine Samples Using a Stable Cannabinoid Reporter System.Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples.Immunoassay screening in urine for synthetic cannabinoids - an evaluation of the diagnostic efficiency.Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples.Reply to 'Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA'.In vitro metabolism of the synthetic cannabinoid 3,5-AB-CHMFUPPYCA and its 5,3-regioisomer and investigation of their thermal stability.Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples.Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA.Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay.Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samplesMetabolites of synthetic cannabinoids in hair--proof of consumption or false friends for interpretation?Extraordinary long detection window of a synthetic cannabinoid metabolite in human urine - Potential impact on therapeutic decisionsDetection and phase I metabolism of the 7-azaindole-derived synthetic cannabinoid 5F-AB-P7AICA including a preliminary pharmacokinetic evaluation
P50
Q28277912-75478EA5-6C29-4AB3-BD7D-E40DFE4C88E6Q33166685-8657B35F-423D-40C2-B0E6-22ACC33A0365Q38644600-D9FDC46C-39EB-4264-BABE-A593F15E6FA1Q38858777-07193F86-C775-4B98-8188-2F27B630B10BQ38994109-AF31E591-A298-4EAC-AEFC-111C4B4538ABQ39508464-A4EB67E3-3506-4AB0-8B8B-2643F44F9297Q42751396-F43615EE-9B2C-471C-844C-ADB8CEA2AEA2Q46594306-2AC15F75-B043-4BD8-802E-1DD866991D06Q47557805-8A17C39B-041E-4107-B83D-115472E1AAEAQ47598189-D251AE10-3E6A-449A-AB00-1319F587DFDAQ49143379-3F560D41-1DAB-4B3E-9C02-3F3CED64D1E3Q56532320-EE4125B6-B49B-45C1-AEE3-5478E084BFB5Q87402638-497D1407-4668-4C51-9479-FF58AC629578Q92686466-C624D806-542A-446A-B284-457686A1BAD0Q93054706-CC1AF9CF-E7CF-448E-B4FB-99733A6D3FE6
P50
description
investigador
@es
researcher
@en
name
Florian Franz
@en
type
label
Florian Franz
@en
prefLabel
Florian Franz
@en
P31
P496
0000-0001-6158-2882